

UNITED STATES DEPARTMENT OF COMMERCE United Stat s Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

		Washing	gion, D.C. 20231	Ŋ
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	Å	TTORNEY DOCKET NO.
09/609,027	06/29/00	HENDRICKSON	W	50950/JPW/EM
-	•	, , , , , , , , , , , , , , , , , , ,	E	XAMINER
		HM12/0508		
JOHN P. WHITE, ESQ.			SHEINE	BERG, M
COOPER & DUNHAM LLP			ART UNIT	PAPER NUMBER
1185 AVENU	E OF THE AME	ERICAS		4
NEW YORK N	Y 10036	·	1631	
			DATE MAILED:	
				05/08/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)			
Office Action Summary		09/609,027	HENDRICKSON ET AL.			
		Examiner	Art Unit			
		Monika B. Sheinberg	1631			
	- The MAILING DATE of this communication app		<u> </u>			
Period fo	• •					
THE - External after or after	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a rep of period for reply is specified above, the maximum statutory period ire to reply within the set or extended period for reply will, by statut reply received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	136 (a). In no event, however, may a reply be t ly within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	imely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).			
1)	Responsive to communication(s) filed on	<u> </u>				
2a)	•	nis action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4)🖂	Claim(s) 1-47 is/are pending in the applicatio	n.				
	4a) Of the above claim(s) is/are withdra	wn from consideration.				
5)	Claim(s) is/are allowed.					
6)	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)⊠	Claims <u>1-47</u> are subject to restriction and/or	election requirement.				
Applicat	ion Papers					
	The specification is objected to by the Examir					
10)🛛	The drawing(s) filed on 29 June 2000 is/are objected to by the Examiner. (See PTO-948)					
11)						
12)	The oath or declaration is objected to by the E	Examiner.				
Priority	under 35 U.S.C. § 119					
13)	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. § 119(a	a)-(d) or (f).			
a)	☐ All b)☐ Some * c)☐ None of:					
	1. Certified copies of the priority documen	ts have been received.				
	2. Certified copies of the priority documen	ts have been received in Applicat	ion No			
* :	Copies of the certified copies of the price application from the International Bushes the attached detailed Office action for a list.	ureau (PCT Rule 17.2(a)).				
	Acknowledgement is made of a claim for dom					
Attachmer	nt(s)					
16) 🔯 No	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s)	19) Notice of Informa	ary (PTO-413) Paper No(s)			

Application/Control Number: 09/609,027

Art Unit: 1631

1

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-6, drawn to a method for preparing a stem cell factor, classified in class
 702, subclass 19.
- II. Claims 7-10, 29-31, and 39-47, drawn to a composition, classified in class 530, subclass 350.
- III. Claim 11-14, and 32-38, drawn to a treatment method, classified in class 514, subclass 2.
- IV. Claims 15-28, drawn to a method of designing a compound, classified in class395, subclass 500.23.

The inventions are distinct, each from the other because of the following reasons:

Groups I, III, and IV, are related as methods. The methods of the Groups I, III, and IV, are each distinct from each other in that Group I is a method of preparing stem cell factor analogs; Group III is a method of treatment; and Group IV is a method for designing a compound.

Groups I, IV, and Group II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case invention II can be made by other means than by a computer as described in group I. The product made can be designed in other ways than described in group IV, such as screening

Art Unit: 1631

compounds for binding capabilities to the stem cell factor receptor in order to select a base design of candidate compounds.

Groups II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method of treatment can be practiced by another meterially different product such as iron supplements for anemic subjects. The product can also be used in a materially different process of using such as a basis for designing a compound capable of binding to a stem cell factor.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/609,027

Art Unit: 1631

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 308-4242, or (703) 308-4028.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Monika B. Sheinberg, whose telephone number is (703) 306-0511. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D., can be reached on (703) 308-4028.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Patent Analyst, Tina Plunkett, whose telephone number is (703) 305-3524, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

May 4, 2001

Monika B. Sheinberg Patent Examiner Art Unit 1631

188